Compare Diamondback Energy Inc (FANG) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Pfizer Inc — how do they compare? Diamondback Energy Inc trades at $200.55 (market cap $56.48B), while Pfizer Inc trades at $26.37 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 2.7× Diamondback Energy Inc's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| FANG | PFE | |
|---|---|---|
Market Cap | $56.48B | $151.73B |
Sector | Energy | Health |
52-Week High | $213.69 | $28.56 |
52-Week Low | $134.53 | $23.60 |
Enterprise Value | $68.63B | $203.22B |
Dividend Yield | 2.18% | 6.46% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $198.97, up 5.81% with strong Q2 2026 earnings beating estimates. Technical indicators show bullish momentum with support at $193 and resistance at $202. Revenue grew to $14.93B in 2025, though profit margins compressed to 11.14%. Analyst consensus is strongly bullish with a $236.63 price target and 90% buy ratings.
FANG offers growth potential through production increases and debt reduction, supported by elevated oil prices. Risks include commodity price volatility and margin pressure from rising costs. The stock trades at a premium P/E of 38.42 but remains attractive given operational efficiency gains and institutional accumulation.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
